Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma-Reference-Cited by-同舟云学术

Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma

Published:2018-03-09 Issue:4 Volume:35 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Igarashi Ryoma,Inoue Takamitsu,Fujiyama Nobuhiro,Tsuchiya Norihiko,Numakura Kazuyuki,Kagaya Hideaki,Saito Mitsuru,Narita Shintaro,Satoh Shigeru,Niioka Takenori,Miura Masatomo,Habuchi Tomonori

Funder

the Japanese Society for the Promotion of Science

AMED-CREST, Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-018-1113-8.pdf

Reference23 articles.

1. Gandaglia G, Ravi P, Abdollah F, et al. Contemporary incidence and mortality rates of kidney cancer in the United States. Can Urol Assoc J. 2014;8:247–52.

2. Tsushima T. Epidemiology of renal cell carcinoma in Japan. Nippon Rinsho. 2017;75:23–6.

3. Sun M, Thuret R, Abdollah F, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 2011;59:135–41.

4. Wahlgren T, Harmenberg U, Sandström P, et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008). Br J Cancer. 2013;108:1541–9.

5. Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014;53:305–25.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Plasma Cabozantinib Concentration With Treatment Response and Adverse Events in Japanese Patients With Advanced Renal Cell Carcinoma;Therapeutic Drug Monitoring;2024-08-29

2. Cabozantinib Induces Isolated Hyperbilirubinemia in Renal Cell Carcinoma Patients carrying the UGT1A1*28 Polymorphism;Clinical Genitourinary Cancer;2024-07

3. Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma;Cancer Biology & Therapy;2024-02-07

4. Quantitative determination of plasma cabozantinib concentration using HPLC–UV and its application to patients with renal cell carcinoma;Biomedical Chromatography;2023-02-21

5. Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer;Cancers;2023-01-03